- Botanix Pharmaceuticals has released its September quarterly report, showing the company ended the period with a strong $22.1M in the bank
- That’s enough cash to keep Botanix going for 8.6 quarters if its operational spend rate remains steady
- In terms of activities, the company reported progress in its BTX 1801 treatment, with data showing the compound effectively kills superbugs
- Botanix also significantly progressed its BTX 1503 acne program after holding a positive meeting with the FDA
- Then the FDA allowed several study waivers normally required for dermatology drug registration, highlighting the safety of BTX 1503
- Shares in Botanix are trading up 15 per cent at 11.5 cents each
